Manila Times Business
Linnaeus Therapeutics Announces Selection of LNS8801 into the National Institute on Aging Interventions Testing Program
Selection by both the NIA ITP and ARPA-H PROSPR programs highlights growing recognition of LNS8801’s potential to promote healthy aging HADDONFIELD, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- Linnaeus Therapeutics, Inc., a privately held company focused on the development and commercialization of small molecule therapeutics for diseases of aging, today announced that its lead drug candidate, LNS8801, has been selected for evaluation in the National Institute on Aging’s (NIA) Interventions Testing P
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Bata, Django, De la Cruz lead coaching staff of new billiards NSA
2h ago
Tokenized Cash Management Advisory Group Publishes the Scope of Its Work Program
2h ago
COSMOBEAUTÉ MALAYSIA & BEAUTYEXPO 2026 RETURNS TO KLCC TO DRIVE B2B EXCELLENCE AND NEW BUSINESS FRONTIERS
2h ago
Regent Hong Kong Named Among First-Ever Winners of Condé Nast Traveler's Triple Crown Award
2h ago